e diseases including AD and ALS and have clarified key molecular steps leading to pathogenic protein aggregation in these disorders; these technologies and discoveries will play key roles in investigations of neurodegenerative mechanisms initiated by some forms of TBI. Dr. Vassilis Koliatsos has a longstanding interest in the clinical, translational, and basic science of brain injury and has the p